Sustained Protection in Mice Immunized with Fractional Doses of Salmonella Enteritidis Core and O Polysaccharide-Flagellin Glycoconjugates

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Simon, Raphael ^a,b   Wang, Jin Y ^a,b   Boyd, Mary A ^a,b   Tulapurkar, Mohan E ^b   Ramachandran, Girish ^a,b   Tennant, Sharon M ^a,b   Pasetti, Marcela ^a,b   Galen, James E ^a,b   Levine, Myron M ^a,b  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORE AND O POLYSACCHARIDE IMMUNOGLOBULIN G ANTIBODY; FLAGELLIN IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; SALMONELLA ENTERITIDIS CORE AND O POLYSACCHARIDE FLAGELLIN SUBUNIT GLYCOCONJUGATE VACCINE; SALMONELLOSIS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACTERIAL IMMUNITY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMORAL IMMUNITY; MORTALITY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN FUNCTION; SALMONELLA ENTERITIDIS; SALMONELLOSIS;

ANIMALS; ANTIBODIES, BACTERIAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; FLAGELLIN; GLYCOCONJUGATES; HUMANS; IMMUNE SERA; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; MICE; O ANTIGENS; SALMONELLA ENTERITIDIS; SALMONELLA INFECTIONS, ANIMAL; SALMONELLA VACCINES; VACCINATION; VACCINES, CONJUGATE;

BACTERIA (MICROORGANISMS); MURINAE; MUS; SALMONELLA; SALMONELLA ENTERITIDIS; SALMONELLA TYPHIMURIUM;

EID: 84878592756     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064680     Document Type: Article

References (30)

1. Jones TF, Ingram LA, Cieslak PR, Vugia DJ, Tobin-D'Angelo M, et al. (2008) Salmonellosis outcomes differ substantially by serotype. J Infect Dis 198: 109-114.
2. Feasey NA, Dougan G, Kingsley RA, Heyderman RS, Gordon MA, (2012) Invasive non-typhoidal Salmonella disease: an emerging and neglected tropical disease in Africa. The Lancet 379: 2489-2499.
3. Simon R, Tennant SM, Galen JE, Levine MM, (2011) Mouse models to assess the efficacy of non-typhoidal Salmonella vaccines: Revisiting the role of host innate susceptibility and routes of challenge. Vaccine 29: 5094-106.
4. Simon R, Tennant SM, Wang JY, Schmidlein PJ, Lees A, et al. (2011) Salmonella enterica serovar Enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. Enteritidis. Infect Immun 79: 4240-4249.
5. Watson DC, Robbins JB, Szu SC, (1992) Protection of mice against Salmonella Typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect Immun 60: 4679-4686.
6. Pollard AJ, Perrett KP, Beverley PC, (2009) Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 9: 213-220.
7. Svenson SB, Nurminen M, Lindberg AA, (1979) Artificial Salmonella vaccines: O-antigenic oligosaccharide-protein conjugates induce protection against infection with Salmonella Typhimurium. Infect Immun 25: 863-872.
8. Lees A, Nelson BL, Mond JJ, (1996) Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents. Vaccine 14: 190-198.
9. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN, (1996) Immunogenicity, efficacy and serological correlate of protection of Salmonella Typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14: 435-438.
10. Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, et al. (2001) The efficacy of a Salmonella Typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 344: 1263-1269.
11. Canh DG, Lin FY, Thiem VD, Trach DD, Trong ND, et al. (2004) Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect Immun 72: 6586-6588.
12. Thiem VD, Lin FY, Canh do G, Son NH, Anh DD, et al. (2011) The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol 18: 730-735.
13. Mai NL, Phan VB, Vo AH, Tran CT, Lin FY, et al. (2003) Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med 349: 1390-1391.
14. Simon R, Levine MM, (2012) Glycoconjugate vaccine strategies for protection against invasive Salmonella infections. Human Vaccines and Immunotherapeutics 8: 494-498.
15. Martin LB, (2012) Vaccines for typhoid fever and other salmonelloses. Curr Opin Infect Dis 25: 489-499.
16. Konadu EY, Lin FY, Ho VA, Thuy NT, Van Bay P, et al. (2000) Phase 1 and phase 2 studies of Salmonella enterica serovar Paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 68: 1529-1534.
17. MacLennan CA, Gondwe EN, Msefula CL, Kingsley RA, Thomson NR, et al. (2008) The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children. J Clin Invest 118: 1553-1562.
18. Acosta CJ, Hong-Hui Y, Ning W, Qion G, Qun D, et al. (2005) Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow-up. Vaccine 23: 5618-5623.
19. Klugman KP, Gilbertson IT, Koornhof HJ, Robbins JB, Schneerson R, et al. (1987) Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 2: 1165-1169.
20. Grossman N, Schmetz MA, Foulds J, Klima EN, Jimenez-Lucho VE, et al. (1987) Lipopolysaccharide size and distribution determine serum resistance in Salmonella Montevideo. J Bacteriol 169: 856-863.
21. Roantree RJ, Rantz LA, (1960) A study of the relationship of the normal bactericidal activity of human serum to bacterial infection. J Clin Invest 39: 72-81.
22. Gondwe EN, Molyneux ME, Goodall M, Graham SM, Mastroeni P, et al. (2010) Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans. Proc Natl Acad Sci U S A 107: 3070-3075.
23. Tennant SM, Wang JY, Galen JE, Simon R, Pasetti MF, et al. (2011) Engineering and preclinical evaluation of attenuated nontyphoidal Salmonella strains serving as live oral vaccines and as reagent strains. Infect Immun 79: 4175-4185.
24. Arya SC, (1999) Efficacy of Vi polysaccharide vaccine against Salmonella Typhi. Vaccine 17: 1015-1016.
25. Arya SC, (1997) Efficacy of Salmonella Typhi Vi capsular polysaccharide vaccine in South Africa. Vaccine 15: 244.
26. Baker S, Sarwar Y, Aziz H, Haque A, Ali A, et al. (2005) Detection of Vi-negative Salmonella enterica serovar Typhi in the peripheral blood of patients with typhoid fever in the Faisalabad region of Pakistan. J Clin Microbiol 43: 4418-4425.
27. Mehta G, Arya SC, (2002) Capsular Vi polysaccharide antigen in Salmonella enterica serovar Typhi isolates. J Clin Microbiol 40: 1127-1128.
28. Robbins JD, Robbins JB, (1984) Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella Typhi. J Infect Dis 150: 436-449.
29. Levy H, Diallo S, Tennant SM, Livio S, Sow SO, et al. (2008) PCR method to identify Salmonella enterica serovars Typhi, Paratyphi A, and Paratyphi B among Salmonella isolates from the blood of patients with clinical enteric fever. J Clin Microbiol 46: 1861-1866.
30. Schmitt CK, Ikeda JS, Darnell SC, Watson PR, Bispham J, et al. (2001) Absence of all components of the flagellar export and synthesis machinery differentially alters virulence of Salmonella enterica serovar Typhimurium in models of typhoid fever, survival in macrophages, tissue culture invasiveness, and calf enterocolitis. Infect Immun 69: 5619-5625.